ClinicalTrials.gg
CompletedNCT00394199Updated Jun 23, 2011

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

A Phase 3 interventional study of Fluticasone propionate/Formoterol Fumarate 100/10 and Fluticasone propionate 100 in Asthma, sponsored by SkyePharma AG. Completed at 41 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2011-06-23.

Sponsored by SkyePharma AG · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
357
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,695 studies in Asthma with a site in United States — 134 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Enrollment
337th of 1,353
357 · median 100
Started
2006
with 82 others
Phase 3
254 of 1,695
14 open now
Registered
222nd of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 337th largest by enrollment of the 1,353 interventional ones that give a count, is one of 83 that started in 2006, is one of 254 in phase 3, and was the 222nd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

134 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

To compare the efficacy and safety of the fixed combination asthma drug Flutiform HFA MDI with its two components administered alone, fluticasone propionate and formoterol fumarate, in adult and adolescent patients with mild to moderate asthma.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Fluticasone Propionate
  • formoterol fumarate
  • Pressurized metered dose inhaler
  • Hydrofluoroalkane
  • Mild to Moderate Asthma
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

  • Ages eligible for study: 12 years and above
  • Genders eligible for study: both
  • Prior use: steroid-requiring or steroid-free

Inclusion criteria

Inclusion Criteria:

  • History of asthma for at least 12 months
  • For steriod-requiring patients, documented use of inhaled corticosteroid for at least 4 weeks prior to Screening Visit
  • For steroid-free patients, no history of inhaled steroid asthma medication for at least 12 weeks prior to Screening Visit
  • Demonstrate FEV-1 of 60-85% of predicted normal values at Screening and Baseline Visit
  • Documented reversibility of 15% within 12 months of Screening or at Screening Visit (15% increase from pre-FEV-1 levels following albuterol inhalation or nebulized albuterol administration)
  • Symptoms of asthma during Run-in
  • Females of must have a negative urine pregnancy test at Screening and Baseline Visits. Females are eligible only if they are not pregnant or lactating, and are either sterile, or using acceptable methods of .
  • Must otherwise be healthy
  • Provide written . Wishes of minors must be respected.

Exclusion criteria

Exclusion Criteria:

Patients will not be eligible for the study if they meet any of the following criteria:

  • Life-threatening asthma within the past year or during the Run-In Period.
  • History of systemic medication within 3 months before the Screening Visit.
  • History of omalizumab use within past 6 months.
  • History of leukotriene receptor antagonist use, e.g., montelukast, within past week.
  • Current evidence or history of any disease or abnormality including uncontrolled hypertension, uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia.
  • Upper or lower respiratory infection within 4 weeks prior to Screening Visit or during Run-In Period.
  • Significant, non-reversible, pulmonary disease (e.g., [COPD], cystic fibrosis, bronchiectasis).
  • Known (HIV)-positive status.
  • Smoking history equivalent to "10 pack years".
  • Current smoking history within 12 months prior to Screening Visit.
  • Current evidence or history of alcohol and/or substance abuse within 12 months prior to Screening Visit.
  • Patients who are confined in institution.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
357 participants (actual)

Study arms

  • Experimental
    1

    FlutiForm 100/10ug

    Drug: Fluticasone propionate/Formoterol Fumarate 100/10

  • Experimental
    2

    Fluticasone 100

    Drug: Fluticasone propionate 100

  • Active comparator
    3

    Formoterol 10

    Drug: Formoterol fumarate 10

Interventions

  • DrugFluticasone propionate/Formoterol Fumarate 100/10

    FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.

    Also known as: Flutiform 100/10

  • DrugFluticasone propionate 100

    Fluticasone 100 is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.

    Also known as: Fluticasone 100

  • DrugFormoterol fumarate 10

    Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.

    Also known as: SKP Formoterol 10

06

What researchers measure

Primary outcomes

  1. Change in Forced Expiratory volume in 1 s (FEV-1) from morning predose at Baseline (Week 0) to predose at Week 12

    Time frame: Week 0 and 12

Secondary outcomes

  1. Other pulmonary function tests including forced vital capacity (FVC) and peak expiratory flow rate (PEFR).

    Time frame: Whole duration of study

  2. Clinical endpoints (frequency of asthma exacerbations and patient data captured in diary including daily morning and evening PEFR).

    Time frame: Whole duration of study

  3. Safety variables include adverse events, ECGs, clinical laboratory tests and vital signs.

    Time frame: Whole duration of study

07

Study locations

41 sites
  • Research Site
    Birmingham, Alabama 35242, United States
  • Research Site
    Mission Viejo, California 92691, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    San Jose, California 95117, United States
  • Research Site
    Vista, California 92083, United States
  • Research Site
    Denver, Colorado 80230, United States
  • Research Site
    Lilburn, Georgia 30047, United States
  • Research Site
    Savannah, Georgia 31406, United States
  • Research Site
    Park City, Kansas 67219, United States
  • Research Site
    Bethesda, Maryland 20814, United States
  • Research Site
    N. Dartmouth, Massachusetts 02747, United States
  • Research Center
    Stevensville, Michigan 49127, United States
  • Research Site
    Elizabeth, New Jersey 07202, United States
  • Research Center
    Rochester, New York 14618, United States
  • Research Site
    Asheville, North Carolina 28801, United States
  • Research Site
    Raleigh, North Carolina 27607, United States
  • Research Site
    Cincinnati, Ohio 45242, United States
  • Research Site
    Sylvania, Ohio 43560, United States
  • Research Site
    Easton, Pennsylvania 18045, United States
  • Research Site
    Lincoln, Rhode Island 02906, United States
  • Research Site
    Greenville, South Carolina 29605, United States
  • Research Site
    Chattanooga, Tennessee 37421, United States
  • Research Site
    El Paso, Texas 79902, United States
  • Research Site
    Houston, Texas 77054, United States
  • Research Site
    Katy, Texas 77450, United States
  • Research Site
    New Braunfels, Texas 78130, United States
  • Research Site
    Waco, Texas 76712, United States
  • Research Site
    South Burlington, Vermont 05403, United States
  • Research Site
    Greenfield, Wisconsin 53228, United States
  • Research Site
    Kelowna, British Columbia V1Y 9L8, Canada
  • Research Site
    Vancouver, British Columbia V5Z 3J5, Canada
  • Research Site
    Hamilton, Ontario L8N 1Y2, Canada
  • Research Center
    London, Ontario N5X 4E7, Canada
  • Research Site
    London, Ontario N6A 1V2, Canada
  • Research Site
    Mississauga, Ontario L4W 1N2, Canada
  • Research Site
    Oshawa, Ontario L1H 1B9, Canada
  • Research Site
    Toronto, Ontario M4P 1P2, Canada
  • Research Site
    Longueuil, Quebec J4N 1E1, Canada
  • Research Site
    Montreal, Quebec H2L 2W5, Canada
  • Research Site
    Saint Foy, Quebec G1V 4M6, Canada
  • Research Site
    Trois Rivieres, Quebec G8T 7A1, Canada
08

References and documents

Publications

  • Pearlman DS, LaForce CF, Kaiser K. Fluticasone/Formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma. Clin Ther. 2013 Jul;35(7):950-66. doi: 10.1016/j.clinthera.2013.05.012. PubMed 23870606 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2006
First posted
Oct 31, 2006
Start
Jun 2006
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results delay requested
Aug 24, 2010
Last update
Jun 23, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00394199
Lead sponsor
SkyePharma AG
First posted
Oct 31, 2006
Start date
Jun 2006
Primary completion
Feb 2008
Completion
Feb 2008
Last update
Jun 23, 2011
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion